dipeptidyl peptidase 1 Dipeptidyl peptidase I (DPP I - Dpp1 Amazon Cathepsin C (CTSC) also known as dipeptidyl peptidase I Dipeptidyl Peptidase 1: A Deep Dive into its Role and Therapeutic Potential

DPP1 inhibitor drugs Dipeptidyl peptidase 1 (DPP-1), also known as Cathepsin C (CTSC), is a crucial enzyme with significant implications in various physiological and pathological processes.作者：D Zhang·2025·被引用次数：1—DPP1 inhibitors have clear potential advantages in bronchiectasis treatment.They directly target neutrophil-mediated inflammatory responses, ... This cysteine protease plays a vital role in the immune response and is recognized for its ability to hydrolyze N-terminal dipeptides from polypeptides. Understanding the function and inhibition of DPP-1 is opening new avenues for therapeutic interventions, particularly in inflammatory respiratory diseases.

The Enzyme: Structure, Function, and Activation

Dipeptidyl peptidase I (DPP I) is a lysosomal exo-cysteine protease belonging to the peptidase C1 protein family. It is an essential enzyme that has dipeptidylpeptidase activity. This activity is critical for the processing and activation of a group of serine proteases primarily found in immune and inflammatory cells, collectively known as neutrophil serine proteases (NSPs).作者：HR Keir·2022·被引用次数：22—Brensocatib is an investigational dipeptidyl peptidase-1 (DPP-1) inhibitor, which has been shown to reduce neutrophilic inflammation in a phase ... During neutrophil maturation, dipeptidyl peptidase 1 (DPP1) is responsible for activating these NSPs, such as neutrophil elastase (NE)Dipeptidyl peptidase 1 inhibition as a potential therapeutic .... This activation process is fundamental for the proper functioning of neutrophils in host defense. The enzyme is a heterododekamer and functions as a thiol protease, meaning it requires a thiol group for its catalytic activity. Its activity is broad, acting against various dipeptide substrates composed of both polar and non-polar amino acids.

The Role of DPP-1 in Inflammation and Disease

The activation of NSPs by DPP-1 is a double-edged sword. While essential for normal immune function, dysregulation of this process can lead to excessive inflammation. This is particularly evident in conditions characterized by neutrophilic inflammation作者：JD Chalmers·2023·被引用次数：39—DPP1 was identified among the highest regulated proteins, and its expression and secretion were elevated in lung metastases of breast cancer. Moreover, high .... Dipeptidyl peptidase 1 (DPP1) exacerbates airway neutrophilic inflammation in bronchiectasis, a chronic respiratory condition marked by airway dysfunction and dilation. In this context, DPP-1 is identified among the highest regulated proteins, with its elevated expression and secretion potentially contributing to the severity of lung metastases in certain cancers.

The involvement of DPP-1 in inflammatory pathways makes its inhibition a promising therapeutic strategy. Pharmacological inhibition of dipeptidyl peptidase 1 aims to reduce the contribution of aberrant NSP activity to the progression of various diseases.作者：JD Chalmers·2023·被引用次数：39—Pharmacological inhibition of dipeptidyl peptidase 1potentially reduces the contribution of aberrant NSP activity to the severity and/or progression of ... By targeting this enzyme, researchers hope to mitigate the downstream inflammatory cascade.

DPP-1 Inhibitors: A New Frontier in Treatment

The development of dipeptidyl peptidase 1 (DPP-1) inhibitors represents a significant advancement in treating inflammatory diseases.Dipeptidyl-peptidase I These compounds are designed to specifically target and inhibit the activity of the DPP-1 enzyme. The rationale behind this approach is that inhibiting DPP-1 can effectively abrogate neutrophilic inflammation.

DPP-1 inhibitors have shown clear potential advantages in treating conditions like bronchiectasisDipeptidyl Peptidase I - an overview. They directly target neutrophil-mediated inflammatory responses, offering a more focused therapeutic approach compared to broader immunosuppressants. By inhibiting NSPs activity, these DPP-1 inhibitors can alleviate neutrophilic inflammation, mitigate aberrant host immune responses, and reduce mucus production.

Brensocatib: A Leading DPP-1 Inhibitor

One of the most prominent examples of a dipeptidyl peptidase inhibitor in development is brensocatib. This investigational drug is an oral, selective, and reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). Clinical trials have demonstrated that brensocatib is an investigational dipeptidyl peptidase-1 (DPP-1) inhibitor and has shown promise in reducing neutrophilic inflammation. Studies have indicated that dipeptidyl peptidase-1 inhibition with brensocatib reduces inflammation in patients hospitalized with certain conditions.Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases The efficacy of brensocatib in bronchiectasis has led to its emergence as a significant therapeutic candidate. In fact, the United States Food and Drug Administration (FDA) approved brensocatib for use in specific patient populations, marking a significant milestone for DPP-1 inhibitor therapy.

Other research compounds also exist, such as DPP-1-IN-1 (Compound 14), an orally active inhibitor of Cathepsin C (also known as Dipeptidyl peptidase I) with a potent IC50 value of 5.31 nM. Furthermore, AZD7986 is another dipeptidyl peptidase 1 (DPP1) inhibitor that has been investigated for its role in activating neutrophil serine proteasesWhat are DPP-1 inhibitors and how do they work? - Patsnap Synapse.

Therapeutic Applications and Future Directions

The therapeutic potential of dipeptidyl peptidase-1 inhibition extends beyond bronchiectasis. Research suggests its application in other inflammatory lung conditions, including cystic fibrosis.作者：MB Long·2025·被引用次数：1—Dipeptidyl peptidase-1 (DPP-1), also known as cathepsin C, processes and activates neutrophil serine proteases. DPP-1 inhibition is therefore considered a promising therapy in development for these conditions.

The enzyme's role in activating neutrophil-derived serine proteases also points to its involvement in other inflammatory conditions, such as acute experimental arthritis. This broadens the scope for DPP-1 inhibitors as potential treatments for a range of diseases driven by inflammatory processes.Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a ...

While the focus has largely been on inflammatory respiratory diseases, the fundamental role of DPP-1 in the immune system suggests its involvement in other biological processes, potentially including negative regulation of myelination and positive regulation of apoptotic signaling pathway, as well as positive regulation of microglial cell activity. Further research into these areas may uncover additional therapeutic targetsDipeptidyl peptidase I (DPP I) is defined as a thiol-dependent enzyme that hydrolyzes N-terminal dipeptides from polypeptides, with the enzyme designated by ....

In summary, dipeptidyl peptidase 1 (DPP-1), synonymous with Cathepsin C, is a vital protease that orchestrates the activation of critical inflammatory enzymes作者：J Zhang·2019·被引用次数：1—Dipeptidyl peptidase 1 (DPP1) is a key enzyme that converts pro-NSPs to an active form. We hypothesized that inhibiting DPP1 activity in .... The development of DPP-1 inhibitors represents a sophisticated therapeutic strategy that directly addresses the root of neutrophilic inflammation, offering new hope for patients suffering from a spectrum of inflammatory disorders.Dipeptidase 1 (DPEP1) is a kidney membrane enzyme that belongs to the peptidase M19 family. DPEP1 is a homodimer and is inhibited by L-penicillamine. DPEP1 ... The ongoing research and clinical application of compounds like brensocatib underscore the significant impact of understanding and targeting this key enzyme. While Dipeptidase 1 (DPEP1) is a related but distinct enzyme, the focus on DPP-1 continues to yield promising therapeutic avenues059. THE REVERSIBLE DIPEPTIDYL PEPTIDASE 1 .... The field is rapidly evolving, with the potential for DPP-1 inhibitors to become standard-of-care in various inflammatory conditions.